IPR Trips Flexibilities Utilization Case Studies
IPR & TRIPS Flexibilities Utilization: Case Studies
The TRIPS Agreement (1995) under WTO sets minimum standards for intellectual property protection. However, it also contains flexibilities for developing countries to balance IP rights with public health, development, and access to technology. Key flexibilities include:
Compulsory licensing (CL) – authorization to produce patented products without patent holder consent.
Parallel imports – importing patented products from other countries without consent.
Bolar exception – research and regulatory exemptions before patent expiry.
Transition periods – extra time for LDCs to comply.
Patentability criteria flexibility – stricter standards for novelty, inventive step, and non-obviousness.
We will analyze case studies illustrating these flexibilities.
1. India – Natco Pharma v. Bayer Corporation (2012)
Flexibility Used: Compulsory Licensing (CL)
Facts:
Bayer held the patent for Sorafenib (Nexavar), an expensive cancer drug.
Natco applied for a compulsory license under Section 84 of Indian Patents Act (TRIPS-compliant).
Court/Authority Decision:
Indian Patent Office granted the CL in 2012.
Reason: Drug was unaffordable for the majority of Indian patients; Bayer was not sufficiently working the patent in India.
Outcome:
Natco allowed to produce and sell generic Sorafenib at 1/10th of Bayer’s price.
Set a landmark precedent for access to essential medicines.
Significance:
Showed TRIPS flexibility for public health can be fully utilized.
Recognized that affordability and accessibility are grounds for CL.
2. Thailand – Compulsory Licensing for HIV and Cancer Drugs (2006-2007)
Flexibility Used: Compulsory Licensing (CL)
Facts:
Thailand issued CLs for Efavirenz (HIV drug, Merck) and several cancer drugs (Novartis and Roche).
Purpose: Lower high drug prices for the public health system.
Outcome:
Authorized local production or import of generics.
Prices dropped by 50–70%, increasing access for patients.
Significance:
TRIPS allows developing countries to issue CL for public health emergencies.
Thailand cited Article 31 of TRIPS and Doha Declaration (2001).
3. Brazil – Government Use of Efavirenz (2007)
Flexibility Used: Government Use (CL variant)
Facts:
Efavirenz patented by Merck.
Brazil issued government-use license to import generics from India.
Legal Basis:
Brazilian law allowed government-use without consent.
Invoked TRIPS Article 31, compliant with public health exception.
Outcome:
Reduced costs for HIV treatment.
Strengthened Brazil’s policy of universal access to medicines.
Significance:
Confirmed TRIPS flexibilities can be directly implemented through government action.
4. South Africa – Medicines Patent Pool & ARVs (2001-2005)
Flexibility Used: Parallel Importation & CLs
Facts:
South Africa faced HIV/AIDS epidemic.
Patented ARVs were unaffordable.
Utilized TRIPS-compliant parallel imports and voluntary CLs to import generics.
Outcome:
Significantly expanded access to HIV drugs.
Reduced mortality rates from AIDS in early 2000s.
Significance:
Demonstrated combined TRIPS flexibilities (CL + parallel imports) for public health.
5. India – Roche v. Cipla (2013)
Flexibility Used: Bolar Exception & Patentability Criteria
Facts:
Cipla wanted to produce generic Tarceva (Erlotinib) for regulatory testing before patent expiry.
Roche challenged under patent infringement.
Decision:
Court recognized Bolar provision under Indian law (Section 107A).
Cipla’s use was for regulatory approval purposes, not commercial sales.
Significance:
Highlighted how TRIPS-compliant exceptions can be used to promote early generic entry.
6. Malaysia – Government CL for Anti-Cancer Drugs (2005)
Flexibility Used: Compulsory Licensing
Facts:
Malaysia issued CL for imatinib (Gleevec).
Drug was expensive, causing public health crisis.
Outcome:
Allowed generic production or import of cheaper alternatives.
Ensured TRIPS compliance while safeguarding public health priorities.
Significance:
Shows that TRIPS allows CL for non-HIV essential drugs too, not only ARVs.
7. Egypt – Parallel Importation of Anti-Cancer Drugs (2011)
Flexibility Used: Exhaustion of Rights / Parallel Importation
Facts:
Egypt imported patented cancer drugs from low-price markets.
Patent holder objected.
Legal Basis:
Invoked TRIPS Article 6 (international exhaustion).
Allowed generic import to improve access.
Outcome:
Patients received drugs at much lower cost.
Significance:
Demonstrated that TRIPS allows flexible IP management for developing countries through parallel importation.
Key Comparative Observations
| Country | TRIPS Flexibility Used | Purpose / Outcome | Notable Impact |
|---|---|---|---|
| India | Compulsory license (Natco v Bayer) | Affordable cancer drug supply | Generic entry at 1/10th price |
| Thailand | CL for HIV/cancer drugs | Lowered drug costs, expanded access | Public health prioritization |
| Brazil | Government-use license | HIV drug access | Reduced public expenditure |
| South Africa | Parallel imports + CLs | HIV/AIDS epidemic control | Expanded ARV coverage |
| India | Bolar exception (Cipla v Roche) | Early generic regulatory approval | Faster market entry post-patent |
| Malaysia | CL for cancer drugs | Cheaper drug supply | Public health emergency response |
| Egypt | Parallel importation | Access to expensive cancer drugs | Lowered cost for patients |
Key Takeaways
TRIPS flexibilities are widely used to promote public health, affordability, and access in developing countries.
Compulsory licensing is the most prominent mechanism.
Bolar exceptions and parallel imports enable early market access without violating TRIPS.
Doha Declaration 2001 reinforces the right of countries to prioritize public health over IP protection.
Case law and government action across India, Thailand, Brazil, Malaysia, South Africa, and Egypt showcase the practical use of flexibilities.
RELATED Blog
comments